PURPOSE: Treatment of prostate cancer with androgen deprivation therapy (ADT) is associated with an increased fat mass, decreased lean mass, increased fatigue and a reduction in quality of life (QoL). The aim of this study was to evaluate the efficacy of a 6-month dietary and physical activity intervention for prostate cancer patients receiving ADT, to help minimise these side effects. METHODS:Patients (n = 94) were recruited to this study if they were planned to receive ADT for prostate cancer for at least 6 months. Men randomised to the intervention arm received a dietary and exercise intervention, commensurate with UK healthy eating and physical activity recommendations. The primary outcome of interest was body composition; secondary outcomes included fatigue, QoL, functional capacity, stress and dietary change. RESULTS: The intervention group had a significant (p < 0.001) reduction in weight, body mass index and percentage fat mass compared to the control group at 6 months; the between-group differences were -3.3 kg (95% confidence interval (95% CI) -4.5, -2.1), -1.1 kg/m(2) (95% CI -1.5, -0.7) and -2.1% (95% CI -2.8, -1.4), respectively, after adjustment for baseline values. The intervention resulted in improvements in functional capacity (p < 0.001) and dietary intakes but did not significantly impact fatigue, QoL or stress scores at endpoint. CONCLUSIONS: A 6-month diet and physical activity intervention can minimise the adverse body composition changes associated with ADT. IMPLICATIONS FOR CANCER SURVIVORS: This study shows that a pragmatic lifestyle intervention is feasible and can have a positive impact on health behaviours and other key outcomes in men with prostate cancer receiving ADT.
RCT Entities:
PURPOSE: Treatment of prostate cancer with androgen deprivation therapy (ADT) is associated with an increased fat mass, decreased lean mass, increased fatigue and a reduction in quality of life (QoL). The aim of this study was to evaluate the efficacy of a 6-month dietary and physical activity intervention for prostate cancerpatients receiving ADT, to help minimise these side effects. METHODS:Patients (n = 94) were recruited to this study if they were planned to receive ADT for prostate cancer for at least 6 months. Men randomised to the intervention arm received a dietary and exercise intervention, commensurate with UK healthy eating and physical activity recommendations. The primary outcome of interest was body composition; secondary outcomes included fatigue, QoL, functional capacity, stress and dietary change. RESULTS: The intervention group had a significant (p < 0.001) reduction in weight, body mass index and percentage fat mass compared to the control group at 6 months; the between-group differences were -3.3 kg (95% confidence interval (95% CI) -4.5, -2.1), -1.1 kg/m(2) (95% CI -1.5, -0.7) and -2.1% (95% CI -2.8, -1.4), respectively, after adjustment for baseline values. The intervention resulted in improvements in functional capacity (p < 0.001) and dietary intakes but did not significantly impact fatigue, QoL or stress scores at endpoint. CONCLUSIONS: A 6-month diet and physical activity intervention can minimise the adverse body composition changes associated with ADT. IMPLICATIONS FOR CANCER SURVIVORS: This study shows that a pragmatic lifestyle intervention is feasible and can have a positive impact on health behaviours and other key outcomes in men with prostate cancer receiving ADT.
Authors: William L Haskell; I-Min Lee; Russell R Pate; Kenneth E Powell; Steven N Blair; Barry A Franklin; Caroline A Macera; Gregory W Heath; Paul D Thompson; Adrian Bauman Journal: Med Sci Sports Exerc Date: 2007-08 Impact factor: 5.411
Authors: H J Green; K I Pakenham; B C Headley; J Yaxley; D L Nicol; P N Mactaggart; C E Swanson; R B Watson; R A Gardiner Journal: BJU Int Date: 2004-05 Impact factor: 5.588
Authors: Farhana Haseen; Liam J Murray; Chris R Cardwell; Joe M O'Sullivan; Marie M Cantwell Journal: J Cancer Surviv Date: 2010-01-21 Impact factor: 4.442
Authors: Derek S Tsang; Jennifer M Jones; Osai Samadi; Suhayb Shah; Nicholas Mitsakakis; Charles N Catton; William Jeon; Joshua To; Henriette Breunis; Shabbir M H Alibhai Journal: Support Care Cancer Date: 2018-03-12 Impact factor: 3.603
Authors: Marquita S Gray; Suzanne E Judd; Richard Sloane; Denise C Snyder; Paige E Miller; Wendy Demark-Wahnefried Journal: Cancer Causes Control Date: 2019-02-19 Impact factor: 2.506
Authors: Elizabeth G Eakin; Sandra C Hayes; Marion R Haas; Marina M Reeves; Janette L Vardy; Frances Boyle; Janet E Hiller; Gita D Mishra; Ana D Goode; Michael Jefford; Bogda Koczwara; Christobel M Saunders; Wendy Demark-Wahnefried; Kerry S Courneya; Kathryn H Schmitz; Afaf Girgis; Kate White; Kathy Chapman; Anna G Boltong; Katherine Lane; Sandy McKiernan; Lesley Millar; Lorna O'Brien; Greg Sharplin; Polly Baldwin; Erin L Robson Journal: BMC Cancer Date: 2015-12-21 Impact factor: 4.430
Authors: Rebecca R Turner; Liz Steed; Helen Quirk; Rosa U Greasley; John M Saxton; Stephanie Jc Taylor; Derek J Rosario; Mohamed A Thaha; Liam Bourke Journal: Cochrane Database Syst Rev Date: 2018-09-19
Authors: Sorrel Burden; Debra J Jones; Jana Sremanakova; Anne Marie Sowerbutts; Simon Lal; Mark Pilling; Chris Todd Journal: Cochrane Database Syst Rev Date: 2019-11-22